Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Eli Lilly & Co ( ($LLY) ) has provided an update. On November 18, 2025, Eli Lilly & Co announced the election of Dr. Carolyn R. Bertozzi to its Board


Eli Lilly Announces New Board Member Election

Earnings reports, acquisitions, and other news are leading the top stock market stories for Friday.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Shares of Danish pharmaceutical Novo Nordisk ($NVO) traded flat on Friday afternoon after its key U.S.-based rival Eli Lilly ($LLY) reached $1 tril...

Novo Nordisk Stock (NVO) Under Pressure as Rival Eli Lilly Joins the $1 Trillion Club

U.S. pharmaceutical giant Eli Lilly & Co. ($LLY) has become the latest company to achieve a $1 trillion market capitalization. The milestone was re...

Eli Lilly Stock (LLY) Surpasses $1 Trillion Market Cap

Eli Lilly (NYSE:LLY) shares have climbed about 22% this month, a trend that has become a regular occurrence of late. Since bottoming out in early A...

‘A Bigger Market Opportunity Awaits,’ Says Truist About Eli Lilly Stock

Several high-profile stocks have split in recent years. 


Will Eli Lilly Stock (LLY) Split? Rumors Are Swirling.

All of the top stock market stories are ready to go in the TipRanks daily wrap-up.


Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Eli Lilly Stock (LLY) Falls as Rival Novo Nordisk Cuts Weight-Loss Drug Prices

Companies in the Financial sector have received a lot of coverage today as analysts weigh in on MetroCity Bankshares (MCBS – Research Report), Jeff...

Analysts Conflicted on These Financial Names: MetroCity Bankshares (MCBS), Jefferson Capital, Inc. (JCAP) and Ally Financial (ALLY)

Insiders have been trading these 5 stocks: (($LLY)), (($GM)), (($IONQ)), (($MRK)) and (($MARA)). Here is a breakdown of their recent trades and the...

Eli Lilly, GM, IonQ, Merck, MARA: Insider Moves Unveiled!

Analysts are intrested in these 5 stocks: ( ($JD) ), ( ($LLY) ), ( ($CCJ) ), ( ($COIN) ) and ( ($MSTR) ). Here is a breakdown of their recent


JD, Eli Lilly, Cameco, Coinbase, and Strategy: Trending by Analysts

Investors continued to dump shares of telehealth company Mangoceuticals ($MGRX) during early trading on Friday. This came after pharmaceutical heav...

Investors Flee Mangoceuticals Stock (MGRX) after Eli Lilly and Novo Nordisk Deny Partnership

Hims & Hers Health’s ($HIMS) shares continued to plunge on Thursday despite the consumer telehealth company launching a new “affordable” healthcare...

Hims & Hers Stock (HIMS) Plunges despite New ‘Affordable’ Healthcare Platform

Traders will find all of the latest stock market stories worth reading about on Thursday in our daily wrap-up.


Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Pfizer’s shares ($PFE) edged higher on Thursday after shareholders of Metsera ($MTSR) approved the American pharma giant’s offer of up to $10 billi...

Pfizer Stock (PFE) Rises as Metsera Shareholders Approve $10B Acquisition

The upcoming weight-loss pill is expected to be a gamechanger. 


Citigroup Sees 50% Upside in Eli Lilly Stock (LLY)

Multiple catalysts are driving the share price higher. 


Eli Lilly Stock (LLY) Hits All-Time High as Post-Earnings Rally Accelerates

The pharma giant has new products coming to market. 


Eli Lilly Stock (LLY) Gets Upgraded as Obesity Drugs Covered by Medicare

Growth stocks represent companies poised for rapid expansion, beating both the overall market and industry peers. This growth potential translates ...

3 “Strong Buy” Growth Stocks to Buy Now, According to Analysts – 11/10/2025

Traders will find all of the hottest stock market stories worth reading today in the TipRanks daily wrap-up.


In a report released today, Jason Strominger from Telsey Advisory maintained a Buy rating on Holley, with a price target of $5.00. Strominger cover...

Telsey Advisory Reaffirms Their Buy Rating on Holley (HLLY)

Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Texas Roadhouse (TXRH – Research Report), Holley (HLLY – R...

Analysts’ Opinions Are Mixed on These Consumer Cyclical Stocks: Texas Roadhouse (TXRH), Holley (HLLY) and Starbucks (SBUX)

Pfizer ($PFE) has reached a deal to buy Metsera ($MTSR), a weight-loss drug startup, in a transaction that could total more than $10 billion. The a...

Pfizer Clinches $10 Billion Metsera Deal as Novo Nordisk Loses Weight-Loss Drug Battle

Insiders have been trading these 5 stocks: (($JPM)), (($ADBE)), (($LLY)), (($MCD)) and (($MRK)). Here is a breakdown of their recent trades and the...

Insider Moves: JPMorgan, Adobe, Eli Lilly, McDonald’s, Merck

The medications had cost $1,000 or more per month. 


Eli Lilly’s Stock (LLY) Falls After Trump Announces Deal to Lower Weight-Loss Drug Prices

Earnings reports, analyst updates, AI deals, and more are among the top stock market stories for Wednesday.


Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Shares of Novo Nordisk ($NVO) fell on Wednesday morning after the Danish drugmaker agreed to a price deal under the U.S. Medicare program for the a...

Novo Nordisk Stock (NVO) Falls after Medicare Price Deal and Q3 Earnings Miss

Eli Lilly Stock (LLY) Rises as Competitor Novo Nordisk Cuts Guidance

Novo Nordisk ($NVO) released its third-quarter fiscal 2025 results, reporting earnings and sales that both fell short of expectations. What’s worse...

NVO Earnings: Novo Nordisk Cuts Guidance amid Rising Weight Loss Drug Competition

Analysts have been eager to weigh in on the Financial sector with new ratings on Ally Financial (ALLY – Research Report) and OneMain Holdings (OMF ...

Analysts Offer Insights on Financial Companies: Ally Financial (ALLY) and OneMain Holdings (OMF)

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Eli Lilly & Co, with a price target of $930.00. The company’...

BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

The company is already manufacturing the medication. 


Eli Lilly (LLY) Says Weight-Loss Pill a Candidate for Fast-Track Approval

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co today and set a price target of $976.00. The company’s shares opened today...

Eli Lilly & Co (LLY) Gets a Buy from Jefferies

Jarden analyst Steven Wheen maintained a Buy rating on CSL yesterday and set a price target of A$287.14. The company’s shares closed today at $114....

Jarden Remains a Buy on CSL (CMXHF)

Earnings reports dominate the stock market headlines worth checking out on Thursday.


The pharma giant is gearing up to release a weight-loss pill. 


Eli Lilly (LLY) Invests $1.2 Billion in Puerto Rico Manufacturing Plant

In a report released on October 27, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly & Co, with a price target of $1,100.00. The ...

Bernstein Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

In a report released today, Ross Law from Morgan Stanley maintained a Hold rating on Thales, with a price target of €260.00. The company’s shares c...

Thales (0IW5) Gets a Hold from Morgan Stanley

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company is spearheading a pivotal Phase 3 clinica...

Eli Lilly’s New Study on Baricitinib: A Potential Game-Changer for Type 1 Diabetes

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is conducting a Phase 3 c...

Eli Lilly’s New Study: Potential Breakthrough in Type 1 Diabetes Prevention

Traders have loads of stock market news to read on Wednesday as earnings and other topics dominate today’s headlines.


In a report released yesterday, Craig Wong-Pan from RBC Capital maintained a Hold rating on CSL, with a price target of A$189.00. The company’s sha...

RBC Capital Reaffirms Their Hold Rating on CSL (CMXHF)

In a report released today, David Bailey from Morgan Stanley maintained a Buy rating on CSL, with a price target of A$248.00. The company’s shares ...

CSL (CMXHF) Receives a Buy from Morgan Stanley

Citi analyst Laura Sutcliffe maintained a Buy rating on CSL today and set a price target of A$230.00. The company’s shares closed today at $112.03....

Citi Sticks to Its Buy Rating for CSL (CMXHF)

Bell Potter analyst Thomas Wakim maintained a Hold rating on CSL today and set a price target of A$195.00. The company’s shares closed today at $11...

CSL (CMXHF) Gets a Hold from Bell Potter

Jim Cramer, the host of CNBC’s Mad Money, shared his outlook on the next group of U.S. companies likely to reach the $1 trillion mark. He named JPM...

Jim Cramer Says One Stock Is Poised to Hit $1 Trillion Soon — Can You Guess Which?

Eli Lilly’s New Phase 3 Trial: A Potential Game-Changer in Bladder Cancer Treatment

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is spearheading a Phase 2...

Eli Lilly’s New Phase 2 Study: A Game Changer for Ulcerative Colitis Treatment?

In a report released today, Brian McNamara from Canaccord Genuity maintained a Buy rating on Holley, with a price target of $6.00. The company’s sh...

Holley (HLLY) Receives a Buy from Canaccord Genuity

Kepler Capital analyst Aymeric Poulain maintained a Buy rating on Thales on October 23 and set a price target of €315.00. The company’s shares clos...

Kepler Capital  Remains a Buy on Thales (0IW5)

Eli Lilly ($LLY) is strengthening its presence in genetic medicine with a deal worth $261.7 million to acquire Adverum Biotechnologies ($ADVM), a c...

M&A News: Eli Lilly’s (LLY) $262M Acquisition of Adverum Bolsters Gene Therapy Push

The company is expanding into eye disease treatments. 


Eli Lilly (LLY) Buys Gene Therapy Developer Adverum for $261 Million

In a report released today, Laura Sutcliffe from Citi maintained a Buy rating on CSL, with a price target of A$265.00. The company’s shares closed ...

Airbus SE ($EADSY), Leonardo SpA ($FINMY), and Thales SA ($THLLY) have agreed to merge their space units into a single company based in Toulouse, F...

Airbus, Leonardo, and Thales Merge Space Units to Challenge SpaceX and Cut Costs

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is conducting a Phase 3 s...

Eli Lilly’s New Phase 3 Study: A Potential Game-Changer for Alcohol Use Disorder

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is spearheading a Phase 3...

Current Quarter	$7.3	Next Quarter	$0.14
Current Year	$23.94	Next Year	$31.98
QoQ Growth	-98.1%	YoY Growth	+33.6%
3Y EPS CAGR	+24.1%	Target Price	$1019.08
Consensus	Buy	Upside	-4.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$1,063.37	+1.92%	2.58M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$1,063.37	+1.9%	2.58M
3
4
5
6

LLY

LLY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel